|
|
| (2 intermediate revisions by the same user not shown) |
| Line 2: |
Line 2: |
| {{CMG}} | | {{CMG}} |
|
| |
|
| ==Hypertrophic Obstructive Cardiomyopathy==
| |
| ===Screening===
| |
| * Athletes should be screened using a family history of sudden death and a murmur on physical examination. Electrocardiograms and echocardiograms are not cost effective in this population.
| |
| ===Prognosis===
| |
| * The myosin binding proteins C genetic variant carries a good prognosis.
| |
| * The presence of VT / VF carries the poorest prognosis. Outflow gradient is also related to prognosis.
| |
|
| |
|
| ===Treatment===
| |
| * Atrial fibrillation in the patient with HOCM should be managed with amiodarone
| |
| * The medical management of the patient with hypertrophic cardiomyopathy involves minimizing diastolic dysfunction, reducing left ventricular outflow tract obstruction, optimizing [[heart failure]] management, maintaining [[normal sinus rhythm]], rate control and anticoagulation in the presence of [[atrial fibrillation]], and implantation of an [[automatic implantable cardiac defibrillator]] in those patients who survive [[sudden cardiac death]].
| |
|
| |
|
| ==References== | | ==References== |
Latest revision as of 00:06, 4 November 2011